ObjectiveThe purpose of this present review was to provide evidence-based guidance regarding the provision of CRS with HIPEC in the treatment of peritoneal cancers.
MethodsThe guideline was developed by Cancer Care Ontario’s Program in Evidence-Based Care, together with the Surgical Oncology Program, through a systematic review of relevant literature, patient and caregiver-specific consultation and internal and external reviews.
Recommendation 1aFor patients with newly diagnosed, primary stage III epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, HIPEC should be considered for those with at least stable disease following neoadjuvant chemotherapy at the time of interval CRS if complete or optimal cytoreduction is achieved.
Recommendation 1bThere is insufficient evidence to recommend the addition of HIPEC when primary CRS is performed for patients with newly diagnosed, primary advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinoma outside of a clinical trial.
Recommendation 2There is insufficient evidence to recommend HIPEC with CRS in patients with recurrent ovarian cancer outside the context of a clinical trial.
Recommendation 3There is insufficient evidence to recommend HIPEC with CRS in patients with peritoneal colorectal carcinomatosis outside of a clinical trial.
Recommendation 4There is insufficient evidence to recommend HIPEC with CRS for the prevention of peritoneal carcinomatosis in CRC outside of a clinical trial; however HIPEC using oxaliplatin is not recommended.Recommendation 5There is insufficient evidence to recommend HIPEC with CRS for the treatment of gastric peritoneal carcinomatosis outside of a clinical trial.
Recommendation 6There is insufficient evidence to recommend HIPEC with CRS for the prevention of gastric peritoneal carcinomatosis outside of a clinical trial.
Recommendation 7There is insufficient evidence to recommend HIPEC with CRS in patients with malignant peritoneal mesothelioma as a standard of care; however, patients should be referred to HIPEC specialty centres for assessment for treatment as part of an ongoing research protocol.
Recommendation 8There is insufficient evidence to recommend HIPEC with CRS in patients with disseminated mucinous neoplasm in the appendix as a standard of care; however, patients should be referred to HIPEC specialty centres for assessment for treatment as part of an ongoing research protocol.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.